Background Osimertinib is recommended for T790M mutation‐positive advanced non‐small
cell lung cancer (NSCLC) resistant to first‐and second‐generation epidermal growth factor …

Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …

Osimertinib is a molecularly targeted agent used to treat non-small cell lung cancer
(NSCLC) patients with an epidermal growth factor receptor (EGFR) T790M mutation …

Background Osimertinib exhibits good efficacy in patients with T790M-positive non-small
cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor …

Background: The third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib is now
the standard therapy for patients with T790M-positive advanced non-small-cell lung cancer …

Background Osimertinib is effective in patients with T790M mutation-positive advanced non-
small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) …

Purpose As a third-generation EGFR TKI has been taken orally, Osimertinib effectively
inhibits mutant EGFR, including T790M EGFR resistance mutations. Here, we examined real …

Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell
lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in …

The discovery of epidermal growth factor receptor (EGFR) mutations and subsequent
demonstration of the efficacy of genotype-directed therapies with EGFR tyrosine kinase …

Osimertinib (Tagrisso™) is an oral, CNS-active, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations …